NCT01904383View on ClinicalTrials.gov

PMS of Trazenta on the Long-term Use as Add-on Therapy

CompletedOBSERVATIONAL
Enrollment

4,057

Participants

Timeline

Start Date

July 1, 2013

Primary Completion Date

October 4, 2018

Study Completion Date

October 4, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Trazenta

1 tablet of 5 mg Trazenta tablets once daily

Trial Locations (1)

Unknown

Multiple Locations

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT01904383 - PMS of Trazenta on the Long-term Use as Add-on Therapy | Biotech Hunter | Biotech Hunter